Champions Oncology, Inc. (CSBR) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2026, Champions Oncology reported revenue of $59.4M, up 4.4% from $56.9M the year before. Net income was -$1.2M (a -2.0% net margin), or -$0.08 per diluted share. Gross margin was 48.0% and operating margin was -1.9%. Operating activities generated -$4.5M of cash, leaving -$5.0M of free cash flow. At fiscal year end, Champions Oncology held $27.0M in total assets against $22.9M in total liabilities.
Open the full interactive Champions Oncology financials → Quarterly statements, key ratios, valuation history and price charts.
Champions Oncology Key Stats
| Share Price | $4.90 |
|---|---|
| Market Cap | $68.1M |
| Revenue YoY Growth | +4.4% |
| 52-Week Range | $4.77 – $7.80 |
| Shares Outstanding | 13.9 million (basic, 2027 Q1) |
Champions Oncology Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $41.0M | $49.1M | $53.9M | $50.2M | $56.9M | $59.4M |
| Cost of Goods Sold | $21.4M | $23.6M | $29.5M | $29.4M | $28.4M | $30.9M |
| Gross Profit | $19.6M | $25.5M | $24.3M | $20.8M | $28.6M | $28.5M |
| Operating Income | $366,000 | $607,000 | -$5.3M | -$7.4M | $4.6M | -$1.1M |
| Pre-Tax Income | $437,000 | $583,000 | -$5.3M | -$7.3M | $4.6M | -$929,000 |
| Income Tax | $75,000 | $35,000 | $68,000 | -$32,000 | -$75,000 | $246,000 |
| Net Income | $362,000 | $548,000 | -$5.3M | -$7.3M | $4.7M | -$1.2M |
| Diluted EPS | $0.02 | $0.04 | -$0.39 | -$0.54 | $0.33 | -$0.08 |
Champions Oncology Quarterly Results
| 2026 Q2 | 2026 Q3 | 2026 Q4 | 2027 Q1 | |
|---|---|---|---|---|
| Revenue | $15.0M | $16.6M | $13.8M | $15.2M |
| Net Income | $268,000 | -$279,000 | -$728,000 | -$426,000 |
| Diluted EPS | $0.02 | -$0.02 | -$0.05 | — |
Champions Oncology Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Current Assets | $12.6M | $19.7M | $19.5M | $13.6M | $22.4M | $19.2M |
| Total Assets | $27.6M | $35.4M | $34.3M | $26.1M | $32.3M | $27.0M |
| Current Liabilities | $11.2M | $17.5M | $21.7M | $21.5M | $23.9M | $19.9M |
| Total Liabilities | $20.2M | $26.3M | $29.7M | $28.0M | $28.6M | $22.9M |
| Shareholders' Equity | $7.4M | $9.1M | $4.6M | -$1.9M | $3.8M | $3.9M |
Champions Oncology Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$1.7M | $6.5M | $4.0M | -$6.1M | $7.4M | -$4.5M |
| Cash From Investing | -$3.2M | -$2.4M | -$2.9M | -$836,000 | -$389,000 | -$540,000 |
| Cash From Financing | $1.2M | $207,000 | $11,000 | -$527,000 | $170,000 | $99,000 |
| Free Cash Flow | -$5.0M | $4.1M | $1.1M | -$6.9M | $7.0M | -$5.0M |
Figures from Champions Oncology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Champions Oncology financials page for every line item.
Champions Oncology Company Profile
| Ticker | CSBR |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Baltimore, Maryland |
| Incorporated in | Delaware |
| Fiscal Year End | April 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000771856 |
Frequently Asked Questions
What was Champions Oncology's revenue in fiscal 2026?
Champions Oncology (CSBR) reported revenue of $59.4M for fiscal 2026.
What is Champions Oncology's annual revenue history?
Champions Oncology's annual revenue by fiscal year: 2021: $41.0M; 2022: $49.1M; 2023: $53.9M; 2024: $50.2M; 2025: $56.9M; 2026: $59.4M.
What was Champions Oncology's net income in fiscal 2026?
Champions Oncology reported net income of -$1.2M for fiscal 2026.
What was Champions Oncology's earnings per share (EPS) in fiscal 2026?
Champions Oncology's diluted EPS was -$0.08 for fiscal 2026 (adjusted for any later stock splits).
How much free cash flow did Champions Oncology generate in fiscal 2026?
Champions Oncology generated -$5.0M of free cash flow in fiscal 2026.
What was Champions Oncology's revenue last quarter?
In its most recent reported quarter (2027 Q1), Champions Oncology reported revenue of $15.2M.
How many shares of Champions Oncology are outstanding?
Champions Oncology reported a weighted average of 13.9 million basic shares outstanding in 2027 Q1.
What is Champions Oncology's market cap?
Based on its latest closing price, Champions Oncology (CSBR) has a market capitalization of about $68.1M.
When does Champions Oncology's fiscal year end?
Champions Oncology's fiscal year end, as registered with the SEC, is April 30.
Where is Champions Oncology headquartered?
Champions Oncology lists its business address in Baltimore, Maryland in its SEC filings.
Champions Oncology Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →